IMA ImageneBio, Inc.

NASDAQ
$3.20

ImageneBio, Inc. (IMA) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.99 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.3% since its last earnings release on November 9, 2026.

ImageneBio Missed Consensus Estimates
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · After Close
Earnings Whisper
-
vs ($0.99)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.50

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ImageneBio, Inc.

Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly known as Ikena Oncology Inc., is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.